Tony McHale standing in his garden, smiling.

Help every man with prostate cancer

Give the gift of research to help every man with prostate cancer live longer, healthier lives.

Donate now

Tony McHale (pictured above) discovered he had an alteration in the BRCA2 gene at the age of 61, putting him at a much higher risk of developing prostate cancer. Shortly after, Tony joined the IMPACT study at the ICR, which investigated whether regular screening would lead to earlier diagnosis of aggressive forms of the disease. Around 18 months later, the screening revealed Tony had prostate cancer. 

"Being involved in the IMPACT study saved my life. If I hadn't taken part, I'd never have known I had prostate cancer. As far as I was aware, I didn't have any symptoms – and the sooner the disease is detected and treated, the better the chances are of survival." – Tony

Godfrey's prostate cancer story

 

DJ and music promoter, Godfrey Fletcher, found out he had prostate cancer in 2015 at the age of 47, shortly after his father had also been diagnosed.

"I was so lucky that my cancer was picked up at a very early stage. I was young and fit, with no symptoms. A year after my treatment finished, I was told it had been successful. My dad wasn't so fortunate. He was diagnosed with advanced prostate cancer and passed away at 80. His experience, and mine, showed me the importance of early diagnosis."

Why we need more research into prostate cancer

We're proud of the research advances we've made over the last 20 years. Our scientists discovered the drug abiraterone; identified genetic variants that influence risk of developing the disease; and pioneered new, more precise forms of radiotherapy. But despite our research advances, some prostate cancers remain difficult to treat. This includes those diagnosed at a later stage and those more aggressive tumours, which can spread quickly and evolve to resist treatment.

That's why we urgently need better ways to detect prostate cancer earlier, predict drug resistance, and develop smarter, more personalised treatments. Your gift will help our world-leading researchers unravel the complexity of prostate cancer, to give men precise and personalised care with the right treatments at the right time, to live longer and healthier lives.

Professor Eeles's goal is to develop new tests that could be used in prostate cancer screening, helping to identify men at a higher risk. Her team showed that a simple saliva test, carried out at home, was more accurate at identifying future risk of prostate cancer for some men than the current standard blood test. 

Building on this success, they recently launched a major new study to find out whether an improved version of this test – now suitable for more diverse groups, including Black men and younger men – can help detect more cancers earlier in men at higher risk. 

Tackling drug resistance

Our research underpinned the development of olaparib, a drug that revolutionised treatment for people with BRCA-related cancers. In a recent study, Professor Johann de Bono's team showed that changes which can be spotted with a simple blood test can reveal how long a prostate cancer patient will respond to olaparib. 

The ability to predict when – and how – patients will stop responding to olaparib could help doctors personalise treatment, and in the future, guide the development of new drugs to outsmart resistance – keeping us one step ahead of prostate cancer.

Professor Johann de Bono in the laboratory, smiling.

Creating smarter, kinder treatments for every man

Our scientists are at the forefront of precision cancer medicine – developing more effective treatments with fewer side effects.

Laboratory studies co-led by Dr Adam Sharp and Professor Johann de Bono showed that NXP800 – a new drug which targets a ‘master switch’ that cancer cells hijack to support their growth – slowed prostate cancer cell growth. This innovative drug could potentially also benefit men with advanced prostate cancer that has stopped responding to standard hormone therapy.

A study co-led by Professor Emma Hall has found that men with intermediate-risk, localised prostate cancer can be treated just as effectively with five sessions of higher-dose radiation therapy as with several weeks of standard treatment. Using stereotactic body radiotherapy (SBRT), which targets tumours with pinpoint accuracy, patients can receive a highly effective treatment with far fewer hospital visits. 

A study co-led by Professor Nick James has shown that a new artificial intelligence (AI) test can select which men with high-risk prostate cancer that has not spread will require the life-extending drug abiraterone. In the STAMPEDE trial, the team found that three out of four men could be spared unnecessary treatment, making the drug – discovered by our scientists – more affordable for the NHS.

Your gift can help every man with prostate cancer live longer, healthier lives

Help someone's dad, grandad, brother, uncle, partner, or friend survive prostate cancer. Your support will help fund life-saving research – so that every man can spend more precious time with their loved ones.

Make a donation

Your gift of research can help transform the lives of every man with prostate cancer.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

Your gift of research can help transform the lives of every man with prostate cancer.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

 Related news and blogs

04/09/25 - by

Jolyon, 75, faced his own cancer diagnosis in 2018 and has also seen members of his immediate family and ‘too many friends’ touched by the disease. That’s why he has pledged to leave a gift in his Will to fund our ground-breaking research.

A few years ago, I just felt that something wasn’t right. Having been involved in sport all my life, I know my body well and I had a sense that something had changed. I was not feeling myself and mentioned it to the doctor. Little did I know I would be diagnosed with early, but aggressive, prostate cancer.

Before this, I had always felt I was unbreakable. The consultant surgeon was brilliant and outlined the options available to me and the immediate need for treatment.

I’m afraid my reaction was both naïve and typical: I asked if I could delay things as I had an important event to work on in a couple of months’ time. My wife’s reaction is unprintable! 

The surgeon looked directly into my eyes and said: “Let me put it this way… You have a cancer which will kill you, but I am going to cure you, unless of course you’d rather I didn’t!”

From that point, I realised I was not indestructible.

Fortunately, the cancer had not spread outside my prostate, and I was lucky to be treated with a non-invasive form of prostatectomy, carried out using robotic surgery. I know that advancements like this have only come about through research and scientific developments.

I am fortunate to have had no further recurrence of disease and feel relieved, grateful and very lucky that I am still here today. I had seen my wife go through breast cancer some years earlier and other family members be diagnosed with cancer too. One or two had died from it. My diagnosis definitely affected my views on cancer research, and I now take a close interest in new developments in this area.

Cancer is more and more prevalent these days and seems to be striking everybody. Despite all the improvements in technology and research, it is still there, touching far too many people. We know much more now than we did previously, but there are so many more discoveries still to make.

We need to improve our ability to diagnose cancer early and to find kinder, more effective treatments to increase survival rates. There simply cannot be enough research into this disease.

The word ‘cancer’ only used to be mentioned in whispers. Now, as research has improved and more people are surviving it, we have more hope that we can get ahead of it and eventually beat the disease. That’s why it made perfect sense to me to leave a gift to the ICR in my Will.

My wife and I had drawn up our Wills many years ago. But having both had run-ins with cancer since then, we decided to update them.

Our solicitor suggested the Will for Free service and sent us details about how it worked. It seemed like a superb idea to us and after reading all about the work of the ICR, we felt it would be a good way to benefit both ourselves and a cause that was incredibly close to our hearts.

It was an easy process and having experienced cancer ourselves, it also felt very meaningful to be able to make a contribution that would ultimately benefit others going through similar experiences.

I am well aware that further research needs funding.  And without it, advances in diagnoses and treatments will not move forward. I am glad to be able to do something to ensure that vital cancer research continues and to contribute to a process that will see others benefit after I am no longer here.

Find out more about leaving a gift in your Will to the ICR and order your free copy of our legacy guide.

Leave a legacy of hope